Algeria Poised to Become Africa’s ‘Pharmacy’: Indo-Algerian Pharma Forum to Unveil Tenshi Group Investment Plans
✍️ 𝓑𝔂: 𝓓𝓻. 𝓗𝓪𝓷𝓪 𝓢𝓪𝓪𝓭𝓪
𝓐𝓵𝓰𝓲𝓮𝓻𝓼 – 𝓙𝓪𝓷𝓾𝓪𝓻𝔂 𝟐𝟎𝟐𝟔 – Algeria is asserting itself as the future “Pharmacy of Africa” with the upcoming Indo-Algerian Pharma Forum, scheduled for Thursday, 15 January 2026. The landmark event, which will convene 90 leading Indian business executives representing 40 Indian companies, will provide a high-level platform for investment, technology transfer, and long-term industrial partnerships. Ahead of the forum, Tenshi Group executives met with a delegation of Algerian journalists in Bengaluru, India, including Dzair Tube’s Editor-in-Chief, to outline the company’s strategic vision and planned investments in Algeria, as well as to discuss the partnership framework with the public pharmaceutical group Saidal.
During the meeting, the executives explained that the choice of Algeria was guided by the country’s strategic investment framework, robust regulatory system, and growing industrial capacity, making it a gateway to African markets. They specifically highlighted four structural pillars underpinning Tenshi’s entry into Algeria:
-
Removal of Entry Barriers: Leveraging Algeria’s new investment law, which permits 100% foreign ownership and full operational control over projects.
-
Financial Security: Guarantees for repatriation of capital and dividends, reinforced by stabilization clauses protecting incentives against future legislative changes.
-
Targeted Fiscal Incentives: Performance-based tax exemptions designed to support projects that align with national priorities.
-
Regulatory Transparency: Streamlined bureaucratic processes, including digital land allocation through the AAPI platform, facilitating full ownership and operational readiness.
Currently, Algeria accounts for 27% of Africa’s pharmaceutical production capacity, meeting 82% of its domestic requirements through 250 operational facilities. The country boasts a regulatory framework rated ML3 by the WHO, a progressive investment law permitting full foreign ownership, and fiscal incentives including full repatriation guarantees for investors. These structural reforms, coupled with Algeria’s strategic geographic position, make it a blueprint for pharmaceutical sovereignty across the continent, as highlighted by Tenshi Group executives during their briefing.
According to them, Tenshi Group, a global pharmaceutical conglomerate and the family office of Arun Kumar, is spearheading this expansion, operating with a $4 billion market capitalization and annual revenue exceeding $1 billion across three strategic platforms:
Publicly Listed Platforms (India):
-
Strides Pharma Science Limited (Generics): Leader in generic medicines with 300+ products approved by stringent regulatory authorities, distributed in over 100 countries.
-
OneSource (Specialty CDMO): Specialising in drug-device combinations, injectables, soft gelatin capsules, and advanced biological drug substances.
-
Solara (API): Active Pharmaceutical Ingredient production ensuring full vertical integration and supply chain security.
Specialty Platforms:
-
Naari (Women’s Health): Focused on reproductive and women’s wellness therapies.
-
InstaPill (Technology Delivery): Lyophilised orally disintegrating tablets for enhanced patient convenience.
-
Serovia (Complex Injectables): Produces dual-chamber sterile bags and other bedside care solutions.
Global Presence: Tenshi maintains 20+ manufacturing facilities across India, the USA, Europe, and Africa, with offices in the USA, UK, Switzerland, Germany, Canada, and Singapore, distributing products to over 100 countries.
Strategic Partnership with Saidal:
The partnership with Algeria’s public pharmaceutical group Saidal forms the backbone of Tenshi’s local strategy. During the Bengaluru briefing, Tenshi confirmed that it will:
-
Establish an integrated production facility covering the full pharmaceutical value chain.
-
Implement technology transfer, R&D collaboration, and API production.
-
Introduce over 30 key medicines in the first phase, creating high-skilled employment opportunities.
-
Upgrade local capabilities to meet international standards, enabling exports to Europe, MENA, and Africa.
The Indo-Algerian Pharma Forum will further facilitate B2B meetings, investment agreements, and regulatory alignment, accelerating Algeria’s transformation into a continent-wide pharmaceutical hub and strengthening bilateral ties with India, a global leader in medicine production and innovation.
— 𝐄𝐍𝐃 —
📡🌍 | 𝓐𝓫𝓸𝓾𝓽 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓜𝓮𝓭𝓲𝓪 𝓖𝓻𝓸𝓾𝓹 | 🌍📡
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
📰 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓲𝓼 𝓪 𝓽𝓻𝓪𝓲𝓵𝓫𝓵𝓪𝔃𝓮𝓻 𝓲𝓷 𝓐𝓵𝓰𝓮𝓻𝓲𝓪𝓷 𝓭𝓲𝓰𝓲𝓽𝓪𝓵 𝓳𝓸𝓾𝓻𝓷𝓪𝓵𝓲𝓼𝓶, 𝓭𝓮𝓵𝓲𝓿𝓮𝓻𝓲𝓷𝓰 𝓱𝓲𝓰𝓱-𝓺𝓾𝓪𝓵𝓲𝓽𝔂 𝓬𝓸𝓷𝓽𝓮𝓷𝓽 𝓲𝓷 𝓐𝓻𝓪𝓫𝓲𝓬, 𝓕𝓻𝓮𝓷𝓬𝓱, 𝓪𝓷𝓭 𝓔𝓷𝓰𝓵𝓲𝓼𝓱. 𝓦𝓲𝓽𝓱 𝓶𝓸𝓻𝓮 𝓽𝓱𝓪𝓷 📈 500,000 𝓭𝓪𝓲𝓵𝔂 𝓬𝓵𝓲𝓬𝓴𝓼, 𝓲𝓽 𝓻𝓪𝓷𝓴𝓼 𝓪𝓶𝓸𝓷𝓰 𝓽𝓱𝓮 𝓶𝓸𝓼𝓽 𝓲𝓷𝓯𝓵𝓾𝓮𝓷𝓽𝓲𝓪𝓵 𝓶𝓮𝓭𝓲𝓪 𝓹𝓵𝓪𝓽𝓯𝓸𝓻𝓶𝓼 𝓲𝓷 𝓽𝓱𝓮 𝓬𝓸𝓾𝓷𝓽𝓻𝔂.🏆 𝓐𝔀𝓪𝓻𝓭𝓮𝓭 𝓽𝓱𝓮 𝓟𝓻𝓮𝓼𝓲𝓭𝓮𝓷𝓽 𝓸𝓯 𝓽𝓱𝓮 𝓡𝓮𝓹𝓾𝓫𝓵𝓲𝓬’𝓼 𝓟𝓻𝓲𝔃𝓮 𝓯𝓸𝓻 𝓟𝓻𝓸𝓯𝓮𝓼𝓼𝓲𝓸𝓷𝓪𝓵 𝓙𝓸𝓾𝓻𝓷𝓪𝓵𝓲𝓼𝓽 𝓲𝓷 𝓽𝓱𝓮 𝓔𝓵𝓮𝓬𝓽𝓻𝓸𝓷𝓲𝓬 𝓟𝓻𝓮𝓼𝓼 𝓬𝓪𝓽𝓮𝓰𝓸𝓻𝔂 (🗓 𝓞𝓬𝓽𝓸𝓫𝓮𝓻 22, 2022), 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓲𝓼 𝔀𝓲𝓭𝓮𝓵𝔂 𝓻𝓮𝓬𝓸𝓰𝓷𝓲𝔃𝓮𝓭 𝓯𝓸𝓻 𝓲𝓽𝓼 𝓮𝓭𝓲𝓽𝓸𝓻𝓲𝓪𝓵 𝓮𝔁𝓬𝓮𝓵𝓵𝓮𝓷𝓬𝓮 𝓪𝓷𝓭 𝓲𝓷𝓽𝓮𝓰𝓻𝓲𝓽𝔂.
📱 𝓜𝓪𝓼𝓼𝓲𝓿𝓮 𝓓𝓲𝓰𝓲𝓽𝓪𝓵 𝓡𝓮𝓪𝓬𝓱:
🔴 600,000+ 𝓨𝓸𝓾𝓣𝓾𝓫𝓮 𝓼𝓾𝓫𝓼𝓬𝓻𝓲𝓫𝓮𝓻𝓼
🔵 6 𝓶𝓲𝓵𝓵𝓲𝓸𝓷+ 𝓯𝓸𝓵𝓵𝓸𝔀𝓮𝓻𝓼 𝓪𝓬𝓻𝓸𝓼𝓼 𝓕𝓪𝓬𝓮𝓫𝓸𝓸𝓴 𝓹𝓪𝓰𝓮𝓼
📸 70,000+ 𝓘𝓷𝓼𝓽𝓪𝓰𝓻𝓪𝓶 𝓯𝓸𝓵𝓵𝓸𝔀𝓮𝓻𝓼🎥 𝓞𝓹𝓮𝓻𝓪𝓽𝓲𝓷𝓰 𝓯𝓻𝓸𝓶 𝓼𝓽𝓪𝓽𝓮-𝓸𝓯-𝓽𝓱𝓮-𝓪𝓻𝓽 𝓼𝓽𝓾𝓭𝓲𝓸𝓼, 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓫𝓻𝓸𝓪𝓭𝓬𝓪𝓼𝓽𝓼 𝓻𝓲𝓬𝓱 𝓪𝓷𝓭 𝓭𝓲𝓿𝓮𝓻𝓼𝓮 𝓹𝓻𝓸𝓰𝓻𝓪𝓶𝓶𝓲𝓷𝓰, 𝓲𝓷𝓬𝓵𝓾𝓭𝓲𝓷𝓰:
🗞 𝓝𝓮𝔀𝓼 | ⚽ 𝓢𝓹𝓸𝓻𝓽𝓼 | 🎭 𝓔𝓷𝓽𝓮𝓻𝓽𝓪𝓲𝓷𝓶𝓮𝓷𝓽 | 🕌 𝓡𝓮𝓵𝓲𝓰𝓲𝓸𝓷 | 🎨 𝓒𝓾𝓵𝓽𝓾𝓻𝓮🗣️ 𝓕𝓮𝓪𝓽𝓾𝓻𝓲𝓷𝓰 𝓲𝓷𝓽𝓮𝓻𝓪𝓬𝓽𝓲𝓿𝓮 𝓽𝓪𝓵𝓴 𝓼𝓱𝓸𝔀𝓼 𝓪𝓷𝓭 𝓮𝔁𝓬𝓵𝓾𝓼𝓲𝓿𝓮 𝓲𝓷𝓽𝓮𝓻𝓿𝓲𝓮𝔀𝓼 𝔀𝓲𝓽𝓱 𝓹𝓻𝓸𝓶𝓲𝓷𝓮𝓷𝓽 𝓯𝓲𝓰𝓾𝓻𝓮𝓼 𝓯𝓻𝓸𝓶 𝓹𝓸𝓵𝓲𝓽𝓲𝓬𝓼, 𝓫𝓾𝓼𝓲𝓷𝓮𝓼𝓼, 𝓪𝓻𝓽𝓼, 𝓪𝓷𝓭 𝓶𝓸𝓻𝓮, 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓼𝓮𝓻𝓿𝓮𝓼 𝓪𝓼 𝓪 𝓴𝓮𝔂 𝓹𝓵𝓪𝓽𝓯𝓸𝓻𝓶 𝓯𝓸𝓻 𝓹𝓾𝓫𝓵𝓲𝓬 𝓭𝓲𝓼𝓬𝓸𝓾𝓻𝓼𝓮 𝓪𝓷𝓭 𝓬𝓲𝓿𝓲𝓬 𝓮𝓷𝓰𝓪𝓰𝓮𝓶𝓮𝓷𝓽.
📰 𝓘𝓽𝓼 𝓹𝓻𝓲𝓷𝓽 𝓼𝓹𝓸𝓻𝓽𝓼 𝓭𝓪𝓲𝓵𝔂, “𝓓𝔃𝓪𝓲𝓻 𝓢𝓹𝓸𝓻𝓽,” 𝓮𝓷𝓳𝓸𝔂𝓼 𝓸𝓿𝓮𝓻 50,000 𝓭𝓪𝓲𝓵𝔂 𝓭𝓸𝔀𝓷𝓵𝓸𝓪𝓭𝓼 𝓿𝓲𝓪 𝓽𝓱𝓮 𝓸𝓯𝓯𝓲𝓬𝓲𝓪𝓵 𝔀𝓮𝓫𝓼𝓲𝓽𝓮—𝓯𝓾𝓻𝓽𝓱𝓮𝓻 𝓬𝓮𝓶𝓮𝓷𝓽𝓲𝓷𝓰 𝓽𝓱𝓮 𝓹𝓵𝓪𝓽𝓯𝓸𝓻𝓶’𝓼 𝓶𝓾𝓵𝓽𝓲𝓶𝓮𝓭𝓲𝓪 𝓵𝓮𝓪𝓭𝓮𝓻𝓼𝓱𝓲𝓹.
🎖️ 𝓗𝓸𝓷𝓸𝓻𝓮𝓭 𝔀𝓲𝓽𝓱 𝓽𝓱𝓮 𝓜𝓮𝓭𝓲𝓪 𝓛𝓮𝓪𝓭𝓮𝓻𝓼𝓱𝓲𝓹 𝓐𝔀𝓪𝓻𝓭 𝓫𝔂 𝓽𝓱𝓮 𝓯𝓸𝓻𝓶𝓮𝓻 𝓜𝓲𝓷𝓲𝓼𝓽𝓮𝓻 𝓸𝓯 𝓒𝓸𝓶𝓶𝓾𝓷𝓲𝓬𝓪𝓽𝓲𝓸𝓷, 𝓜𝓸𝓱𝓪𝓶𝓮𝓭 𝓛𝓪â𝓰𝓪𝓫, 𝓪𝓷𝓭 𝓬𝓮𝓵𝓮𝓫𝓻𝓪𝓽𝓮𝓭 𝓪𝓽 𝓽𝓱𝓮 𝓗𝓲𝓵𝓪𝓵𝓼 𝓸𝓯 𝓽𝓱𝓮 𝓣𝓮𝓵𝓮𝓿𝓲𝓼𝓲𝓸𝓷 𝓪𝔀𝓪𝓻𝓭𝓼, 𝓓𝔃𝓪𝓲𝓻 𝓣𝓾𝓫𝓮 𝓬𝓸𝓷𝓽𝓲𝓷𝓾𝓮𝓼 𝓽𝓸 𝓵𝓮𝓪𝓭 𝔀𝓲𝓽𝓱 𝓲𝓷𝓷𝓸𝓿𝓪𝓽𝓲𝓸𝓷, 𝓲𝓷𝓯𝓵𝓾𝓮𝓷𝓬𝓮, 𝓪𝓷𝓭 𝓲𝓶𝓹𝓪𝓬𝓽.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
🌐 𝓢𝓽𝓪𝔂 𝓒𝓸𝓷𝓷𝓮𝓬𝓽𝓮𝓭:
🔗 𝓦𝓮𝓫𝓼𝓲𝓽𝓮: www.dzair-tube.dz
🔗 𝓔𝓷𝓰𝓵𝓲𝓼𝓱: www.dzair-tube.dz/en
📲 𝓕𝓸𝓵𝓵𝓸𝔀 𝓾𝓼 𝓸𝓷 𝓕𝓪𝓬𝓮𝓫𝓸𝓸𝓴 | 𝓘𝓷𝓼𝓽𝓪𝓰𝓻𝓪𝓶 | 𝓨𝓸𝓾𝓣𝓾𝓫𝓮
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
